EMAIL THIS PAGE TO A FRIEND

BMC biotechnology

Development of a high yield expression and purification system for Domain I of Beta-2-glycoprotein I for the treatment of APS.


PMID 26576675

Abstract

In this paper we describe a novel method to achieve high yield bacterial expression of a small protein domain with considerable therapeutic potential; Domain I of Beta-2-glycoprotein I (β2GPI). β2GPI is intrinsic to the pathological progression of the Antiphospholipid Syndrome (APS). Patients develop autoantibodies targeting an epitope located on the N-terminal Domain I of β2GPI rendering this domain of interest as a possible therapeutic. This new method of production of Domain I of β2GPI has increased the production yield by ~20 fold compared to previous methods in E.coli. This largely scalable, partially automated method produces 50-75xa0mg of pure, folded, active Domain I of β2GPI per litre of expression media. The application of this method may enable production of Domain I on sufficient scale to allow its use as a therapeutic.